Skip to content

Efficacy study of Nutrilite All Plant Protein Booster on the improvement of osteoarthritis and sarcopenia at middle-aged and elderly: A randomized, double-blind, placebo-controlled study

Efficacy study of Nutrilite All Plant Protein Booster on the improvement of osteoarthritis and sarcopenia at middle-aged and elderly: A randomized, double-blind, placebo-controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056415
Enrollment
Unknown
Registered
2022-02-05
Start date
2022-01-26
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis and sarcopenia

Interventions

Group 1:Plant dipeptide protein powder
Group 2:Plant protein
Group 3:Maltodextrin

Sponsors

Jinhua Wenrong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Men and women with OA&SA who were 50 to 70 years old with a K&L rating of mild or moderate (grade 1 or 2) and who met the SARC-CalF rating; 2.During the study, subjects agreed not to take any drugs, supplements, or performance enhancers; 3.During the study, subjects agreed not to participate in any OA&SA-related physical therapy; 4.Subjects are willing to comply with all research requirements and procedures; 5.Subjects have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Subjects in other similar studies on dairy or probiotic products in the last 6 months; 2.Currently taking medication for cardiovascular or metabolic diseases; 3.Subjects had flu/virus symptoms within 3 months prior to first visit to laboratory; 4.Have any of the following medical history or be diagnosed to have the following diseases: obvious gastrointestinal disorders, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases, which may affect the evaluation of the study results; 5.Current or historical abuse of alcohol or prohibited performance-enhancing drugs, supplements, or prescription OTC drugs; 6.Suffer from any gastrointestinal disorders or gastrointestinal diseases, including but not limited to allergic bowel syndrome, enteritis, ulcerative colitis, celiac disease; 7.Within 3 months prior to screening or currently receiving medical or nutritional treatment, including protein supplementation or the use of substances that provide exercise capacity; 8.Weight gain or weight loss of more than 5KG in the 3 months before screening; 9.History of hospitalization 3 months prior to screening; 10.In the judgment of the investigator, there is frequent use of medications that may affect electrolyte balance or hydration. ;

Design outcomes

Primary

MeasureTime frame
Grip strength;Short Physical Performance Battery (SPPB);Western Ontario and McMaster Universities Osteoarthritis Index;

Secondary

MeasureTime frame
MRI;DXA;Inbody;Chalder Fatigue Scale (CFQ 11);SARC-CalF;SF36;Biochemical indicators;

Countries

China

Contacts

Public ContactWu Tao

Sprim (Shanghai) Consulting Co., Ltd.

charlie.zhang@sprimmedical.com+86 13641673915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026